Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 06, 2025, titled "Press Release".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.4 pts less than Nifty Microcap 250 and 7.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals reported FY25 revenue of ₹2,687 Mn, up 28.8% YoY, with Q4 FY25 revenue at ₹586 Mn (up 34.7% YoY). Operating EBITDA for FY25 grew 59.1% to ₹579 Mn, with margin expanding 410 basis points to 21.5%, driven by the Yash Pharma acquisition integration and disciplined cost management. Business PAT (excluding the exceptional gain from the Faridabad facility sale) rose 66.7% to ₹375 Mn in FY25, while reported PAT stood at ₹554 Mn including the one-time divestment gain. The Board has recommended a 125% dividend (₹2.5 per share), and the company ended the year with a healthy cash balance of ₹1,456 Mn and zero debt. Net working capital cycle was sharply reduced from 59 days in FY22 to 13 days in FY25, and brand Indocap crossed the ₹50 Cr milestone.
Strong double-digit revenue and profit growth, meaningful margin expansion, and a higher dividend payout signal robust operational momentum and shareholder-friendly capital allocation, likely to be viewed positively by the market. The zero-debt balance sheet and improved working capital cycle give the company room to fund further organic and inorganic growth.